Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.13p
   
  • Change Today:
    -0.055p
  • 52 Week High: 3.42
  • 52 Week Low: 0.85
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 2,365,381
  • Market Cap: £8.85m
  • RiskGrade: 328

ImmuPharma confirms continued FDA delays for Lupuzor

By Josh White

Date: Friday 11 Sep 2020

LONDON (ShareCast) - (Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.
The AIM-traded firm said that, in its discussions with its Lupuzor licensing partner Avion Pharmaceuticals, Avion confirmed that while the review period by the FDA for an SPA request was normally up to 45 days, which had now passed, Avion had still not received a response from the FDA.

"As such, the file is still in the review queue, due to the current workload at the FDA," the board explained in its statement.

"ImmuPharma will provide an update to the market as soon as Avion has received a response from the FDA and notified ImmuPharma."

At 1205 BST, shares in ImmuPharma were down 5.01% at 12.8p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.13p
Change Today -0.055p
% Change -2.52 %
52 Week High 3.42
52 Week Low 0.85
Volume 2,365,381
Shares Issued 416.44m
Market Cap £8.85m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.25% below the market average65.25% below the market average65.25% below the market average65.25% below the market average65.25% below the market average
18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average
Price Trend
4.11% below the market average4.11% below the market average4.11% below the market average4.11% below the market average4.11% below the market average
47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:17 14,000 @ 2.08p
16:13 22,386 @ 2.20p
16:13 9,454 @ 2.20p
16:13 10,000 @ 2.15p
16:12 15,000 @ 2.15p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page